Peter Kenneth Gillman

PsychoTropical Research, Bucasia, QLD, Australia.

2 papers in the library · 10 citations · publishing 2024-2026

Papers

Hypertensive Emergency Secondary to Combining Psilocybin Mushrooms, Extended Release Dextroamphetamine-Amphetamine, and Tranylcypromine

Journal of Psychoactive Drugs June 21, 2024 Peter Kenneth Gillman, Brian S. Barnett, Curtis J. Koons et al. 9 citations

A 42-year-old man with treatment-resistant depression experienced a hypertensive emergency with chest pain, palpitations, headache, and ST-elevation on electrocardiogram about half an hour after taking 1 g of Psilocybe cubensis mushrooms while on tranylcypromine, extended-release dextroamphetamine-amphetamine, and other medications. He was diagnosed with a myocardial infarction, treated with lorazepam, nitroglycerin, and aspirin, and underwent cardiac catheterization that showed no significant abnormalities. He was discharged after overnight hospitalization with no lasting physical effects. The authors suspect phenylethylamine in the mushrooms interacted with the MAOI and amphetamine to cause the event, noting past studies suggest classic serotonergic psychedelics alone with MAOIs should not produce such emergencies.

DOI: 10.1080/02791072.2024.2368617 Psilocybin Tranylcypromine Dextroamphetamine Medicine +3

Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data.

CNS drugs January 17, 2026 Gaëlle Rached, Anna Campana, Dimitri Fiani et al. 1 citation

Monoamine oxidase inhibitors (MAOIs) can be used safely in some patients who use psychoactive substances, but certain combinations pose potentially fatal risks. This narrative review of 219 publications found that combining MAOIs with amphetamines, the empathogen MDMA, opioids with strong serotonergic reuptake inhibition (e.g., meperidine, tramadol), or alcoholic beverages high in tyramine can lead to serotonin toxicity, hypertensive emergencies, or death. In contrast, MAOI treatment of patients who use low-tyramine alcohol, caffeine, cannabis, nicotine, sedatives, and some classic hallucinogens can likely be managed with careful monitoring. No robust human data support MAOIs as effective treatments for substance use disorders themselves.

DOI: 10.1007/s40263-025-01256-7 Full text